Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 16/20 | 0.55 |
| ▸ | JAK2 | O60674 | 13/20 | 0.55 |
| ▸ | JAK1 | P23458 | 8/20 | 0.55 |
| ▸ | TYK2 | P29597 | 5/20 | 0.55 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050577 | 1.00 | JAK3 (0.55) | JAK3JAK2JAK1TYK2AKT1 | |
| SCHEMBL1050223 | 0.91 | JAK3 (0.54) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL10321067 | 0.91 | JAK3 (0.54) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL10319155 | 0.89 | JAK3 (0.58) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL1049611 | 0.89 | JAK3 (0.58) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL10277416 | 0.87 | BTK (0.54) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL10316950 | 0.87 | BTK (0.54) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL16144760 | 0.87 | BTK (0.54) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL10277246 | 0.86 | JAK3 (0.52) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL12958068 | 0.86 | JAK3 (0.52) | JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | JAK3 3/4885JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.